natgillin/translations-raw huggingface dataset:
The present invention is thus directed to a modified soluble FGF receptor Fc comprising a fusion of a soluble fragment or domain of a FGF receptor with an Fc region of an immunoglobulin, wherein at least the 5th N-glycosylation site of the FGF receptor moiety is occupied, and wherein at most 45% of the N-glycans of the FGF receptor moiety have no sialyl group. 
HR P20110503 T1 PATENTNI ZAHTJEVI Modificirana fuzija između topivog FGF receptora i Fc, gdje je to fuzija između topivog fragmenta ili domene FGF receptora s Fc područjem imunoglobulina, naznačena time što prosječni broj jedinica sialinske kiseline po Nglikanu u FGF receptorskom ostatku je 0,9 ili veći.
Although thiazolidinediones have been shown to increase insulin sensitivity by binding to PPARY receptors, this treatment also produces unwanted side effects such as weight gain and edema and, for troglitazone, liver toxicity. 
Iako se pokazalo da tiazolidindioni povisuju osjetljivost na inzulin vezanjem na receptore PPARYy, ovo liječenje također dovodi do neželjenih nuspojava, poput porasta tjelesne težine i edema, a kod troglitazona i hepatotoksičnost.
In the early stage of the closing movement (starting from the open state of the extraction module) the closure force is relatively low (and the closure speed relatively high). 
U ranoj fazi kretanja pri zatvaranju (polazeći od otvorenog položaja modula za ekstrakciju) sila zatvaranja je relativno mala (a brzina zatvaranja relativno velika).
The method of any one of claims 1 - 4 wherein said alcoholism is early-onset alcoholism or late-onset alcoholism. 
Metoda iz bilo kojeg od patentnih zahtjeva 1-4 pri čemu je navedeni alkoholizam alkoholizam koji nastupa rano ili alkoholizam koji nastupa kasno.
A monoclonal antibody that specifically binds to a polypeptide comprising the amino acid sequence as shown in SEQ ID NO:3 or SEQ ID NO:4. 
Monoklonsko protutijelo koje se specifično veže na polipeptid s aminokiselinskim slijedom prikazanim za SEQ ID N0.:3 i SEQ ID No.:4.
and A− an anion formally derived from a pharmaceutically acceptable acid; 
A_je anion koji se formalno izvodi od farmaceutski prihvatljive kiseline, njene farmaceutski prihvatljive soli, enantiomera i enantiomerne smjese.
A device according to claim 6 characterized in that there are distance disks (8) and pressing sleeves (7) situated at the end of the crossbar (6). 
Naprava prema zahtjevu 7, naznačena time, da su distantne pločice (8) i stezni rukavci (7) postavljeni na krajevima traverze (6).
A process according to any one of claims 1 to 25 wherein the amount of the resolution agent ranges from 0.5 to 1,5 equivalents calculated on the sum of the stereoisomeric forms of 6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthalenyl-B-phenyl-3-quinolineethanol present in the mixture under a). 
Postupak prema bilo kojem od zahtjeva 1 do 25 naznačen time da je količina sredstva za razlučivanje u rasponu od 0.5 do 1,5 ekvivalenata računano na bazi zbroja stereoizomernih oblika 6-bromo-a-[2-(dimetilamino)etil]-2-metoksi-a-1-naftalenil-B-fenil-3-kinolinetanola koji se nalazi u smjesi iz koraka a).
The process of claim 5, wherein the water soluble species comprise charged species and neutral species and the ratio by weight of the total amount of charged species to the total amount of neutral species in the soaking liquid is in a range selected from the group consisting of 20:100 to 90:100, 40:100 to 80:100, and 50:100 to 80:100. 
Proces iz patentnog zahtjeva 5, gdje u vodi topljive vrste sadrže naelektrizirane vrste i neutralne vrste i odnos po masi ukupne količine naelektrizirane vrsta prema ukupnoj količini neutralnih vrsta u tekućini za natapanje je u opsegu odabranom iz grupe koja se sastoji od 20:100 do 90:100, 40:100 do 80:100, 1 50:100 do 80:100.
substituted and unsubstituted heteroaryl, substituted and unsubstituted heterocyclyl, and substituted and unsubstituted cycloalkyl; and 
(6) supstituirani i nesupstituirani heterociklil, i (D) supstituirani i nesupstituirani cikloalkil; i
and R9 taken together with the nitrogen atom to which they are attached form a non-aromatic heterocyclic ring containing 2-6 carbon atoms which is: 
RÅ i R*, uzeti zajedno s dušikom na kojeg su vezani, tvore nearomatski heterociklički prsten s 2-6 atoma ugljika koji je:
Use of an antibody or antigen-binding fragment according to claim 19, whereby the combined hormone therapy is an estrogen plus progestin therapy. Use of the antibodies according to claim 1 and 2 or in form of a pharmaceutical composition according to claim 10 comprising PRLR antibodies or antigen-binding fragment according to claim 1 and 2 for parenteral administration, whereby methods of parenteral delivery include topical, intra-arterial, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration. 
Uporaba antitijela prema bilo kojem od zahtjeva 1 do 4 ili u obliku farmaceutskog pripravka u skladu sa zahtjevom 11 naznačena time da sadrži PRLR antitijela ili fragment koji veže antigene prema bilo kojem od zahtjeva 1 do 4 naznačen time daje za pripremu farmaceutske formulacije za parenteralnu primjenu, pri čemu postupci parenteralne primjene uključuju lokalnu, intraarterijsku, intramuskularnu, potkožnu, intramedularnu, intratekalnu, intraventrikularnu, intravenoznu, intraperitonealnu, intrauterinu, vaginalnu, ili intranazalnu primjenu.
On the basis of the data received by respective acquisition circuit 7a, 7b, microprocessor 6a, 6b independently selects an appropriate telegram from telegram memory 8a, 8b on the basis of predetermined (known) internal rules. 
Na osnovi podataka primljenih odnosnim akvizicijskim komunikacijskim krugom 7a, 7b, mikroprocesor 6a, 6b nezavisno odabire odgovarajući telegram iz memorije telegrama Ba, &b na osnovi predodređenih (poznatih) unutarnjih pravila,
is a lower alkylene group or a lower alkenylene group; 
Boje Cig alkilen skupina ili C2 4 alkenilen skupina;
wherein said HDAC inhibitor is a compound of the following formula or a pharmaceutically acceptable salt thereof: 
(a) HDAC inhibitor, pri čemu je HDAC inhibitor spoj sa sljedećom formulom: i
to 80 wt.%, particularly 1 to 80 wt.%, preferably 10 to 60 wt.% and more preferably 30 to 50 wt.% of said enteric coating material; 
do 80 masenih %, posebno 1 do 80 masenih %, poželjno 10 do 60 masenih % i najpoželjnije 30 do 50 masenih % navedenog enteričkog obložnog materijala;
The emulsion of claim 1, wherein the non-ionic lipophilic surfactant is present at a concentration of 0.2% to 1.2% expressed as a weight by volume of emulsion (w/v). 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je neionski lipofilni tenzid prisutan s koncentracijom od 0,1% do 2,5% izraženom kao masa po volumenu emulzije (masa/volumen).
a coating layer (D) selected among a layer of fabric, natural leather, synthetic leather or non-woven fabric. 
– pokrovnog sloja (D), kojeg se bira između sloja tkanine, prirodne kože, umjetne kože ili netkanog materijala.
According to an alternative embodiment of the invention, steps e) and f) are replaced by the steps, at the central monitoring system, of e1′) extracting a set of parameters or another quality-related representation from the error free stream, e2′) modifying the extracted set of parameters or representation on the basis of the list of lost packet identifiers, and f) evaluating the modified parameter set or stream representation for deriving a quality score for the transmission along the transmission chain. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što korake e) i f) zamjenjuju koraci, u središnjem sustavu za praćenje, e1*) vađenja skupa parametara iz struje bez grešaka, e2') modificiranja izvađenog skupa parametara na osnovi spiska identifikatora izgubljenih paketa i f) procjenjivanja modificiranog skupa parametara radi dobivanja razine kvalitete prijenosa duž lanca prijenosa.
The method of item 21 wherein the subject is suffering from a disorder selected from Alzheimer's Disease and schizophrenia. 
Farmaceutski sastav iz patentnog zahtjeva 3 za uporabu u metodi liječenja kognitivnog gubitka kod subjekta koji pati od Alzheimerove bolesti.
Ki values are calculated from competition binding data using non-linear least squares regression using the Prism software package (GraphPad Software). 
Vrijednosti K; su izračunate iz podataka za kompeticijsko vezanje, pomoću nelinearne regresije najmanjih kvadrata, uz upotrebu softverskog paketa Prism (GraphPad Software),
contacting a compound of formula (II): with a carboxylic acid activating reagent selected from the group consisting of thionyl halides, anhydrides and thioester generating reagents; in a compatible solvent; brominating the product of step (a) with bromine in a compatible solvent; 
Ž (ID sa reagensom za aktiviranje karboksilne kiseline odabranim iz grupe koja se sastoji od tionil- halida, anhidrida 1 tioestar-generirajućih sredstava; u kompatibilnom otapalu; (b) bromiranje proizvoda iz koraka (a) bromom u kompatibilnom otapalu;
Use of a pharmaceutical composition according to any one of claims 1-38 for the manufacture of a pharmaceutical comprising a combination of Compound I and one or more antidiabetic compounds other than Compound I for treating Type II diabetes, wherein Compound I has the formula 
Upotreba farmaceutske kompozicije prema bilo kojem od patentnih zahtjeva 1-38 za proizvodnju lijeka koji sadrži kombinaciju spoja I i jednog ili više antidijabetičkih spojeva koji so razlikuju od spoja I za liječenje dijabetesa tipa II, pri čemu spoj I ima formulu 45.
filtering the reference pixels of a current luma block adaptively based on the luma intra prediction mode and the size of the luma transform unit; generating prediction blocks of the current luma block and a current chroma block using the adaptively filtered reference pixels; 
jedinicu (350) za filtriranje referentnih piksela konfiguriranu da adaptivno filtrira referentne piksele tekućeg luma bloka na osnovi luma intrapredikcijskog režima i veličine luma transformacijske jedinice i da ne filtrira referentne piksele tekućeg kroma bloka;
Determination of Number of Cells 
Broj međunarodne prijave:
The compound according to claim 1 wherein R1 is —C1-4alkyl or R1 is selected from the following groups: 
Spoj prema zahtjevu 1, 2 ili 3, naznačen time, da R' je -C,.alkil ili je R' odabran od sljedećih skupina:
Floor panel according to any of the preceding claims, characterized in that the male and the female part comprise contact surfaces (51-52) at their distal extremities, said contact surfaces (51-52) being performed upwardly inclined in distal direction. 
Podni panel sukladno bilo kojem od prethodnih zahtjeva, naznačen time što je element zaključavanja (12) pružen u udubini (13) i time što, je u slobodnom nespojenom stanju, i dalje smješten zajedno sa svojim dijelom za zaključavanje (17) barem djelomice unutar udubine (13).
Precipitated material can conveniently be collected by centrifugation. 
Istaloženi se materijal pogodno može sakupiti centrifugiranjem.
filtering the solution using cotton, wherein the opioid antagonist is present in said extract in a weight percent amount, based on the total amount of opioid antagonist in the dosage form, that is more than 15 %-points less than the weight percent amount of opioid agonist present in the extract, based on the total amount of opioid agonist in the dosage form, and wherein the opioid antagonist is naloxone or a pharmaceutically acceptable salt thereof, and the opioid agonist is selected from pharmaceutically acceptable salts of any of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone. 
filtracija otopine kroz pamuk, gdje je opioidni antagonist prisutan u ekstraktu u količini u težinskom postotku, na temelju ukupne količine opioidnog antagonista u dozirnom obliku, a to je više od 15%-bodova manje od težinskog postotka opioidnog agonista u ekstraktu, na temelju ukupne količine opioidnog agonista u dozirnom obliku, i gdje je opioidni agonist oksikodon hidroklorid, a opioidni antagonist je nalokson hidroklorid, u dozirnom obliku su prisutni u omjeru količina 2:1.
A single-frequency simulcast radio communication network, comprising a plurality of repeater stations, each of the plurality of repeater stations including a circuit according to claim 17 . 
Jednofrekventna izravna radio komunikacijska mreža (N), naznačena time, da sadrži veliki broj repetitorskih stanica (S) prema zahtjevu 17.
at least one sensor, said sensor(s) being adapted to measure a physical parameter which is relatable to a lying position used by a user; and 
barem jedan senzor (31; 31'; 31"), pri čemu je navedeni senzor (senzori) prilagođen za mjerenje fizičkog parametra koji je povezan s ležećim položajem koji koristi korisnik;
The pharmaceutical composition of any one of claims 11-14 for use in a method of treating an immune disease. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 11-14 za primjenu u metodi liječenja imunološke bolesti.
preparing a compound of formula 40 via the Suzuki coupling reaction of a compound of formula 42 with a compound of formula 41; 
pripravu spoja s formulom 40 putem reakcije Suzukijevog sparivanja spoja s formulom 42 sa spojem s formulom 41;
The pharmaceutical composition of at least one of the aspects 1-11 for use in treating at least one metabolic syndrome and/or atherosclerosis. 
Farmaceutski pripravak za uporabu prema barem jednom od zahtjeva 1-11, naznačen time što dijabetes je dijabetes tipa 2.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound fenpropimorph. 
CH, naznačen time da je Ry difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj klorotalonil.
lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatine; the hard gelatine capsules are preferably enteric coated as described above. 
laktoza, saharoza, sorbit, manit, krumpirov škrob, kukuruzni škrob, amilopektin, derivati celuloze ili želatina; kapsule su prvenstveno obložene izvana kao što je gore opisano.
Z is a radical selected from 
Z je radikal odabran od sb)
A composition of coating suspension (calculated on dry material) is particularly preferred which comprises: 
Posebno poželjan sastav oblagajuće suspenzije (izračunato na osnovu suhog materijala) sadrži:
An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što dodavanje razrjeđivača uzorku ljudske stolice kako bi se dobilo razrijeđeni uzorak uključuje dodavanje smjese fiziološke otopine i polietilen-glikola uzorku ljudske stolice.
wherein the cancer is a prostate cancer, a prostate carcinoma or a metastasis thereof. The method as claimed in claim 1, wherein said monitoring of said disease comprises determining regression, course or onset of said disease in a sample from a patient who has said disease or is suspected of falling ill with said disease. 
Postupak prema bilo kojem od patentnih zahtjeva 6 do 9 naznačen time što navedeno praćenje navedene bolesti kancera sadrži određivanje regresije, toka ili početka navedene bolesti u uzorku od pacijenta koji ima navedenu bolest ili za koga se sumnja da se razboljeva od navedene bolesti.
Compound 27 was obtained as a white solid from compound 26 and methyl 4-aminobenzoate by method C. 
Spoj 27 se dobiva kao bijela krutina iz spoja 26 i metil 4-aminobenzoata pomoću postupka C,
A composition comprising at least about 9% by weight terbinafine or a pharmaceutically acceptable salt thereof, hydroxypropyl chitosan, a lower alkanol and water for use in treating onychomycosis in a patient, wherein said composition is applied to the affected areas of said patient once weekly. 
Pripravak koji sadrži najmanje oko 9 % masenog udjela terbinafina ili njegove farmaceutski prihvatljive soli, hidroksipropil hitozan, niži alkanol 1 vodu za primjenu u liječenju onihomikoze kod pacijenta, naznačen time, što se spomenuti pripravak nanosi na pogođena područja pacijenta jednom tjedno.
1, 2 and 3, mixing member 1 also comprises a number of scraping devices 7 located on outer lateral edges 4 b of longitudinal blades 4, and each designed to slide uninterruptedly on the inner cylindrical surface of bowl 2 to prevent the ingredient mixture inside bowl 2 from adhering to the lateral wall of the bowl. 
Referirajući se na Slike 1, 2 13, članak za miješanje također sadrži određen broj strugala 7 lociranih na vanjskim bočnim bridovima 4b uzdužnih lopatica 4, a svaka je dizajnirana da neprekidno klizi po unutarnjoj cilindričnoj plohi zdjele 2 da se spriječi prianjanje smjese sastojaka unutar zdjele 2 na bočnu stijenku zdjele.
% based on the outer layer, and (b) Shea butter in an amount of 55 to 80 wt. 
% bazirano na vanjskom sloju, i (b) mekani biljni maslac u količini od 55 do 80 mas.
Immobilized metal ion affinity chromatography is preferably carried out on a chelating resin, such as chelating sepharose. 
Afinitetna kromatografija s imobiliziranim metalnim ionima poželjno se provodi na helirajućem nosaču poput helirajuće sefaroze.
C5-C10 aryl, C5-C10 heteroaryl, or C5-C10 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or 
R? je Cs-Cio aril, Cs-Cio heteroaril, ili Cs-C19 heteroarilalkil, od kojih je svaki po izboru supstituiran sa od 1 do 5 R?" grupa; ili
The method of claim 1, wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is administered up to three times or more a day for as long as the subject is in need of treatment for the hematologic malignant neoplastic disorder. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli daje tri ili više puta dnevno sve dok je subjektu potrebno liječenje akutne mijeloične leukemije (AML).
a clutch mechanism; and 
- mehanizam spojke (20), i
FIG. 3 is a cross-section on the line III-III of FIG. 
je poprečni presjek duž linije III-III iz slike 2, slika 4
During this mixing phase, a liquid, e.g. water or water with a part of the sugar replacer composition, is sprayed through a bottom or a top spray nozzle. 
Tijekom faze miješanja, tekućina, a to može biti čista voda ili voda s dijelom sastavine koja zamjenjuje šećer, raspršuje se kroz mlaznicu s dna ili s vrha spremnika.
Racemic compounds of the present invention can also be resolved into their optical antipodes, e.g. by fractional crystallization. The compounds of the present invention may also be resolved by the formation of diastereomeric derivatives. 
Racemički spojevi ovdje predočenog izuma mogu se pretvoriti u njihove optičke antipode i frakcionalnom kristalizacijom spojevi ovdje predočenog izuma mogu se pretvarati formacijom diastereomeričkih derivata.
The following abbreviations are employed in the Schemes, Examples and elsewhere herein: 
U Prikazima, Primjerima i svuda drugdje koriste se slijedeće kratice:
The composition of claim 6, wherein the composition is free of rasagiline base that is not ionically bonded to the tannate. 
Sastav prema patentnom zahtjevu 6, naznačen time, da u sastavu nema rasagilinsku bazu koja nije ionski povezana na tanat.
The alkylation according to method 1 is conveniently performed in an organic solvent such as a suitably boiling alcohol or ketone, preferably in the presence of an organic or inorganic base (potassium carbonate, duisopropylethylamine or triethylamine) at reflux temperature. 
Alkilacija u skladu s metodom 1 prikladno se vrši u organskom otapalu kao što je to odgovarajući kipući alkohol ili keton, po mogućnosti u prisutnosti jedne organske ili anorganske baze (kalijev karbonat diizopropiletilamin ili trietilamin) na refluks temperaturi.
A compound of claim 1 or 2, wherein R2 is phenyl optionally substituted with NHSO2(1-4C alkyl). 
Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je R2 fenil izborno supstituiran s NHSO2(1-4C alkilom).
- 3000 g /l glyphosate and/or glufosinate or an agrochemically acceptable salt thereon, in solution in the aqueous phase; 
3000 g/l glifosata i/ili glufosinata ili njihove agrokemijski prihvatljive soli, u otopini u vodenoj fazi;
LDPC encoding the BCH-encoded L1 signaling data to generate LDPC parity bits; and performing puncturing on the generated LDPC parity bits. 
LDPC-kodiranje BCH-kodiranih signalnih podataka LI zbog stvaranja LDPC paritetnih bitova; i probijanje na stvorenim LDPC paritetnim bitovima.
The method of claim 8, wherein the agent for treatment of hypertension is an angiotensin-converting an enzyme inhibitor, an angiotensin II receptor blocker, a diuretic, a beta-blocker, or a calcium channel blocker. 
(c) sredstvo za liječenje hipertenzije je inhibitor enzima za pretvaranje angiotenzina, blokator receptora angiotenzina II, diuretik, beta-blokator, ili blokator kanala kalcija; ili
The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof according to claim 2, wherein R1 represents hydrogen, a C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group, a benzyl group, or a tri-C1-C6 alkylsilyloxy-C1-C6 alkyl group; and R4 represents any of a phenyl group, 
Spoj predstavljen formulom (1) ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 2, naznačen time, da R1 predstavlja vodik, C1-C6 alkilnu skupinu, hidroksi- C1-C6 alkilnu skupinu, benzilnu skupinu ili tri- C1-C6 alkilsililoksi- C1-C6 alkilnu skupinu; i R4 predstavlja bilo koju od
a C6-14 aryl-C1-6 alkyl group (wherein C6-14 aryl is optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B), or 
CÂ«_14 aril-C,.galkil skupina (gdje C4.14 aril je opcijski supstituiran sa 1 do 5 istih 1li različitih supstituenata izabranih iz gore navedene skupine B) ili
the lipid:protein molar ratio in said starting suspension is from about 2:1 to about 200:1; and said first temperature range includes temperatures no less than 10 degrees below and no more than 15 degrees above the transition temperature of said protein component and said second temperature range includes temperatures no less than 10 degrees below and no more than 5 degrees above the transition temperature of said lipid component; 
(iv) molarni omjer lipid: protein u navedenoj početnoj suspenziji je od oko 2:1 do oko 200: 1; i (v) navedeni prvi temperaturni raspon obuhvaća temperature ne manje od 10 stupnjeva ispod i ne više od 15 stupnjeva iznad temperature prijelaza navedene proteinske komponente i navedeni drugi temperaturni raspon obuhvaća temperature ne manje od 10 stupnjeva ispod 1 ne više od 5 stupnjeva iznad temperature prijelaza navedene lipidne komponente;
In a further example, the invention provides an isolated recombinant antibody, (or a functional protein comprising an antigen binding portion thereof) comprising a full length heavy chain and a full length light chain, wherein: the full length heavy chain comprises an amino acid sequence that is at least 80%, or at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs 75-78; the full length light chain comprises an amino acid sequence that is at least 80%, or at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs 71-74; the antibody specifically binds to BAFFR, and the antibody exhibits at least one of the following functional properties: it inhibits BLyS induced B cell proliferation, or BLyS induced IgG1 production and it depletes B cell in vitro or in vivo. 
Protutijelo ili funkcionalni protein prema bilo kojem od zahtjeva 1 do 4, naznačen/o time, da obuhvaća jaki lanac pune duljine, koji se sastoji od aminokiselinske sekvence koja je najmanje 95% identična aminokiselinskoj sekvenci odabranoj iz skupine koju čine od SEQ ID NO:75 do SEQ ID NO:78 i slabi lanac pune duljine, koji se sastoji od aminokiselinske sekvence koja je najmanje 95% identična aminokiselinskoj sekvenci odabranoj iz skupine koju čine od SEQ ID NO:71 do SEQ ID NO:74. Protutijelo ili funkcionalni protein prema zahtjevu 5, naznačen/o time, da obuhvaća sljedeće: